Moreover, the high plasma ctDNA levels in patients harboring a KRAS A146–mutated tumor were accompanied by high plasma ctDNA levels for other genes like TP53, TERT, and PIK3CA (Figure 3 in Data Supplement), implying that high plasma ctDNA levels for KRAS A146–mutated tumors are associated with tumor burden. This evidence concerns the gene KRAS and neoplasm.